Navigation Links
Novel nanotherapeutic delivers clot-busting drugs directly to obstructed blood vessels
Date:7/5/2012

Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University have developed a novel biomimetic strategy that delivers life-saving nanotherapeutics directly to obstructed blood vessels, dissolving blood clots before they cause serious damage or even death. This new approach enables thrombus dissolution while using only a fraction of the drug dose normally required, thereby minimizing bleeding side effects that currently limit widespread use of clot-busting drugs.

The research findings, which were published online today in the journal Science, have significant implications for treating major causes of death, such as heart attack, stroke, and pulmonary embolism, that are caused by acute vascular blockage by blood thrombi.

The inspiration for the targeted vascular nanotherapeutic approach came from the way in which normal blood platelets rapidly adhere to the lining of narrowed vessels, contributing to the development of atherosclerotic plaques. When vessels narrow, high shear stresses provide a physical cue for circulating platelets to stick to the vessel wall selectively in these regions. The vascular nanotherapeutic is similarly about the size of a platelet, but it is an aggregate of biodegradable nanoparticles that have been coated with the clot-busting drug, tissue plasminogen activator (tPA). Much like when a wet ball of sand breaks up into individual grains when it is sheared between two hands, the aggregates selectively dissociate and release tPA-coated nanoparticles that bind to clots and degrade them when they sense high shear stress in regions of vascular narrowing, such as caused by blood clot formation.

Disruption of normal blood flow to the heart, lung, and brain due to thrombosis is one of the leading causes of death and long-term adult disability in the developing world. Today, patients with pulmonary embolism, strokes, heart attacks, and other types of acute thrombosis leading to near-complete vascular occlusion, are most frequently treated in an acute care hospital setting using systemic dosages of powerful clot-dissolving drugs. Because these drugs can cause severe and often fatal bleeding as they circulate freely throughout the body, the size of the dosage given to any patient is limited because efficacy must be balanced against risk.

The new shear-activated nanotherapeutic has the potential to overcome these efficacy limitations. By targeting and concentrating drug at the precise site of the blood vessel obstruction, the Wyss team has been able to achieve improved survival in mice with occluded lung vessels with less than 1/50th of the normal therapeutic dose, which should translate into fewer side effects and greater safety. This raises the possibility that, in the future, an emergency technician might be able immediately administer this nanotherapeutic to anyone suspected of having a life-threatening blood clot in a vital organ before the patient even reached the hospital.

The inter-disciplinary and inter-institutional collaborative research team, which was led by Wyss Founding Director Donald Ingber M.D., Ph.D., and Wyss Technology Development Fellow Netanel Korin, Ph.D., also included Wyss postdoctoral Fellow Mathumai Kanapathipillai, Ph.D., as well as Benjamin D. Matthews, Marilena Crescente, Alexander Brill, Tadanori Mammoto, Kaustabh Ghosh, Samuel Jurek, Sidi A. Bencherif, Deen Bhatta, Ahmet U. Coskun, Charles L. Feldman, and Denisa D. Wagner from Brigham and Women's Hospital, Children's Hospital Boston, Harvard Medical School, the Harvard School of Engineering and Applied Sciences, and Northeastern University. Ingber is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Children's Hospital Boston, and Professor of Bioengineering at Harvard's School of Engineering and Applied Sciences.

Commenting on the work, Ingber noted that "the vascular nanotherapeutic we developed that selectively becomes activated in regions of high shear stress, much like living platelets do, is a wonderful example of how we at the Wyss Institute take inspiration from biology, and how biomimetic strategies can lead to new and unexpected solutions to age-old problems that existing technologies can't address."


'/>"/>

Contact: Twig Mowatt
twig.mowatt@wyss.harvard.edu
Wyss Institute for Biologically Inspired Engineering at Harvard
Source:Eurekalert  

Related biology technology :

1. Novel clay-based coating may point the way to new generation of green flame retardants
2. Soligenix Announces Collaboration with Infectious Disease Research Institute to Develop Thermostabilized Biodefense Vaccines Utilizing Novel Adjuvants
3. BioMotiv Launches Novel Drug Development Operation, Names Leadership Team
4. State-of-the-Art Novelda NVA6000 Impulse Radar Transceiver Finds Widespread Appeal and Applications
5. Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
6. Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
7. Novel radiation surveillance technology could help thwart nuclear terrorism
8. X-BODY BioSciences to Present Novel Methods of Selecting for Antibodies Against Targets on Live Cells at CHIs Protein Engineering Summit
9. Novel compound halts tumor spread, improves brain cancer treatment in animal studies
10. Islet Sciences Announces DiaKine Therapeutics Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection
11. Cellectricon Launches Dynaflow® Resolve System Enabling Novel Ion Channel Assays
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Novel nanotherapeutic delivers clot-busting drugs directly to obstructed blood vessels
(Date:1/19/2017)... and GAITHERSBURG, Md. ... MKT: PIP) and Altimmune, Inc., a privately-held immunotherapeutics ... of a definitive agreement for the merger of ... current investors include Novartis Venture Fund, HealthCap, Truffle ... be a fully-integrated and diversified immunotherapeutics company with ...
(Date:1/19/2017)... ... January 19, 2017 , ... FireflySci Inc. is a go-getter type ... tremendous growth is accounted to two main factors. The first is the amazing ... of vendors supplying FireflySci products all around the world. , 2016 was a tremendous ...
(Date:1/19/2017)... N.J. , Jan. 18, 2017 BD (Becton, Dickinson ... company, announced today that it will host a live webcast of ... 1 p.m. (ET). The webcast can be accessed ... available for replay through Tuesday, January 31, 2017. ... About BD BD is ...
(Date:1/18/2017)... 2017   Parent Project Muscular Dystrophy (PPMD) , ... Duchenne muscular dystrophy (Duchenne) , today announced a $600,000 ... of Technology (NJIT) and Talem Technologies (Talem) as part ... to assist people living with Duchenne. PPMD is ... an embedded computer, software, a force sensor and a ...
Breaking Biology Technology:
(Date:1/4/2017)... LAS VEGAS , Jan. 4, 2017  For the thousands of ... , a global leader in connected health and biometric measurement devices and ... pressure monitors. On display in A&D Medical,s special CES ... monitors represent the ongoing expansion of the company,s WellnessConnected product ... ...
(Date:12/20/2016)... -- The rising popularity of mobility services such ... significant interest in keyless access systems. Following the ... (BLE), biometrics and near-field communication (NFC) are poised ... technologies in the automotive industry. This evolution from ... opens the market to specialist companies such as ...
(Date:12/16/2016)... NEW YORK , Dec. 16, 2016 The global ... reach USD 12.14 billion by 2021 from USD 5.31 billion in ... ... market is mainly driven by technological advancements in medical devices, launch ... devices, rising preference for wireless connectivity among healthcare providers, and increasing ...
Breaking Biology News(10 mins):